Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) recovered 0.25% of its value since hitting low of $32.18. The recent move of -5.28% drop pushed the stock to close at $32.26 when trading ended on 6/12/2019. At a recent session, the prices were hovering between $33.8 and $35.03. This company shares are 143.34% off its target price of $78.5 and the current market capitalization stands at $1.46B. The recent change has given its price a -20.15% deficit over SMA 50 and -56.84% deficit over its 52-week high. The stock witnessed -17.66% declines, -32.75% declines and -19.45% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AERI’s volatility during a week at 5.72% and during a month it has been found around 4.57%.Aerie Pharmaceuticals, Inc. (AERI) Top Holders
Institutional investors currently hold around $1.63 billion or 0% in AERI stock. Look at its top three institutional owners: Wellington Management Group Llp owns $215.21 million in Aerie Pharmaceuticals, Inc., which represents roughly 14.74% of the company’s market cap and approximately 13.23% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 4,108,461 shares of the stock are valued at $139.93 million. The third largest holder is Blackrock Inc., which currently holds $103.1 million worth of this stock and that ownership represents nearly 7.06% of its market capitalization.
At the end of March reporting period, 107 institutional holders increased their position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by some 6,673,336 shares, 67 decreased positions by 8,407,910 and 24 held positions by 32,694,670. That puts total institutional holdings at 47,775,916 shares, according to SEC filings. The stock grabbed 37 new institutional investments totaling 3,008,969 shares while 20 institutional investors sold out their entire positions totaling 3,404,884 shares.Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insider Trades
Multiple company employees have indulged in significant insider trading. Aerie Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Scientific Officer Kopczynski Casey C. has sold 11,000 shares of Aerie Pharmaceuticals, Inc. (AERI) in the trading session dated Feb. 01, 2019. These shares are worth $507,870 and were traded at $46.17 each. The SEC filing shows that Kopczynski Casey C. performed a sale of 11,000 shares. The Chief Scientific Officer disposed these shares by way of transaction on Jan. 02, 2019. The company’s shares were given away at $35.21 per share worth to an income of some $387,310 to the account of Kopczynski Casey C..
Chief Scientific Officer, Kopczynski Casey C., sold 11,000 common shares of Aerie Pharmaceuticals, Inc. (AERI) in the open market. In a transaction dated Dec. 03, 2018, the shares were put up for sale at an average price of $39.81, raking in a sum of $437,910. After this sale, 117,743 common shares of AERI are directly owned by the insider, with total stake valued at $3,798,389.
In the transaction dated Nov. 16, 2018, a great number of shares acquired came courtesy the Director; Cagle Gerald D. added a total of 2,000 shares at an average price of $41.75, amounting to approximately $83,500. The insider now directly owns 19,800 shares worth $638,748.
Several analysts have released their opinion on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), with 4 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 7 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation [T1].